New data on the use of hospital drugs to support Covid-19 research


New data is being collected on which drugs are prescribed and administered in hospitals to support Covid-19 research.

NHS Digital has established the hospital administration and prescription resource to collect data on a daily basis from electronic prescription and administration systems.

The data comes from NHS secondary care trusts in England and is currently limited to those using electronic prescribing and administration (EPMA) systems provided by WellSky.

The collection will be expanded to include data on drugs from a second cohort of trusts using Cerner, which will be published in the fall of 2021.

Steven Marks, NHS Digital’s program director, said: “Until recently there was no central information available at the level of secondary care patients to help understand and investigate hospital prescribing practices, so this data quality will provide a critical insight into how the infection is being managed in all NHS organizations in response to Covid-19 ”.

By linking the data to other NHS Digital data, it will help to:

  • Support the identification of groups of patients who may be at greater risk of harm if they take Covid-19, or demonstrate where certain medicines may provide greater protection or poorer outcomes
  • It provides information on how drugs have been used to treat patients with Covid-19 in hospitals
  • Understand prescribing patterns before, during and after Covid-19
  • Model the impact that the treatment of serious infections, including antibiotics, antivirals, and antifungals, has on patient outcomes

Ann Slee, CCIO’s NHSX Drug Associate, added: “This is a big step forward and forms the basis for the national long-term collection of EPMA data that will support numerous medication safety initiatives and other over-prescriptions. .

“It will help us further develop the right standards to sustain the hospital prescription and deepen our understanding and approach to managing challenges such as antimicrobial resistance.”

Data will only be provided to those who can provide sufficient evidence to support their need, such as researchers and those involved in drug policy.

Source link